$ cat ./records/gates-foundation-funds-aeras-inhaled-tuberculosis-vaccine-deliver-2010.txt
Gates Foundation Funds Aeras Inhaled Tuberculosis Vaccine Delivery for Needle-Free Lung Immunity
[RECORD.TXT] · cat --full
The Gates Foundation, through its long-term funding relationship with the Aeras Global TB Vaccine Foundation, supported research into inhaled tuberculosis vaccine delivery systems designed to induce mucosal and lung immunity directly at the site of TB infection. Conventional injectable TB vaccines do not produce the lung-resident T cell responses that researchers believe are necessary to prevent pulmonary disease. Aeras's inhaled delivery programme explored adenoviral vector and lipid-nanoparticle formats that could deliver antigens via aerosol or dry-powder inhalation without injection.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Bill and Melinda Gates pledge $10 billion for a 'Decade of Vaccines'
Next →
Gates Foundation Grand Challenges Grant to Johns Hopkins for Malaria Mosquito Kill-Switch Pathogen
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.